Twist Bioscience Executive Sells Over $10K in Company Stock

Twist Bioscience Corp recently disclosed in a company filing that Dennis Cho, the Senior Vice President, Chief Legal Officer & Corporate Secretary, has sold shares of the company’s common stock. The filing reveals that Cho sold a total of 234 shares at an average price of $46.941 each, leading to a total transaction value of about $10,984.

This transaction occurred on September 20, 2024, as part of fulfilling tax withholding obligations related to the vesting of Restricted Stock Units. The company’s equity incentive plans require such sales to meet tax obligations through a “sell to cover” transaction. Importantly, this action was not discretionary for Cho but rather a necessary step as per the company’s equity plans.

After this sale, Cho retains ownership of 78,393 shares of Twist Bioscience Corp, reflecting his ongoing commitment to the company’s future. Based in South San Francisco, California, Twist Bioscience is known for its innovative approaches within the field of synthetic biology.

Insider transactions like this are closely monitored by investors and market analysts as they often provide insight into the company’s financial health and the confidence its executives have in its prospects. However, it is not uncommon for such transactions to be part of pre-established financial planning by company insiders.

This filing was executed by Judy Yan, acting as Attorney-in-Fact for Dennis Cho, and dated September 24, 2024.

In other recent developments, Twist Bioscience reported a substantial 28% increase in revenue year-over-year for the fiscal third quarter of 2024, amounting to $81.5 million. Additionally, the company improved its gross margin to 43.3%, with aspirations to surpass 50% by the end of fiscal 2025. Twist Bioscience projects a 27% rise in total revenue for fiscal 2024 compared to the previous year, with expected Q4 revenue falling between $82 million and $83 million.

Baird has reaffirmed a positive outlook on Twist Bioscience, maintaining an Outperform rating. Their analysis highlights the rising pricing premiums for the company’s Express Genes service, particularly noted among academic institutions.

The company has expanded its DNA synthesis capabilities, now offering gene fragments up to 5.0 kilobases. In collaboration with bitBiome Inc., Twist Bioscience has also introduced a Transaminase Enzyme Screening Kit aimed at providing a more environmentally friendly solution for synthesizing chiral amines, which are vital components in drug manufacturing. These advancements are part of Twist Bioscience’s ongoing operational and strategic initiatives.

In the stock market, Twist Bioscience Corp has shown considerable performance, with notable share price volatility. The company’s market capitalization is around $2.72 billion, reflecting its scale within the biotechnology sector.

Analysts are not anticipating profitability for the current year, evidenced by a Price to Earnings (P/E) ratio of -12.24, indicating the company is currently operating at a loss. The adjusted P/E ratio for the past twelve months as of Q3 2024 is also negative at -15.1. However, Twist Bioscience has achieved a significant 122.66% gain in total return over the past year.

Additionally, the Price to Book (P/B) ratio is currently at 5.57, indicating the stock trades at a premium compared to the company’s book value, which could be a crucial point for potential investors to analyze. Moreover, the company’s liquid assets exceed its short-term obligations, indicating a favorable financial position.

For those keen to explore Twist Bioscience’s financials and operational metrics, further insights on its debt levels, dividend policy, and relevant investment considerations are available through detailed resources.

This article was produced with the assistance of AI and underwent editorial review.